CBG Topicals Surge as Hemp Industry Shifts Beyond CBD Dominance

CBG-based topical products are emerging as one of the hemp industry's fastest-growing segments as consumers increasingly seek alternatives to CBD for targeted relief and recovery applications.

The cannabinoid, which stood in CBD's shadow for years, is now driving significant product innovation in topical formulations. Brands are developing CBG creams, balms, and recovery-focused products that appeal to athletes, wellness enthusiasts, and consumers looking for cannabinoid options beyond the saturated CBD market.

Market Shift

The growth reflects broader changes in consumer cannabinoid preferences. While CBD dominated hemp product development since the 2018 Farm Bill legalized hemp cultivation, manufacturers now face intense competition and margin pressure in that category. CBG represents a differentiation opportunity—and early sales data suggests consumers are receptive.

Topical applications appear particularly well-suited to CBG's properties. Unlike CBD, which interacts primarily with the endocannabinoid system's CB1 and CB2 receptors, CBG acts as a precursor cannabinoid that converts into other compounds in the cannabis plant. This molecular difference has sparked interest from formulators developing targeted wellness products.

But the science remains limited. Most CBG research comes from preclinical studies, and the FDA hasn't evaluated cannabinoid topicals for medical claims. That hasn't stopped brands from marketing CBG products for post-workout recovery, skin health, and general wellness—claims that exist in regulatory gray areas.

Production Challenges

CBG's rise comes with supply chain complications. The cannabinoid occurs in much lower concentrations in hemp plants compared to CBD, making extraction more expensive. Hemp cultivators typically harvest plants early in the growth cycle to maximize CBG content, which reduces overall biomass yields.

Some genetics companies now offer CBG-rich hemp cultivars that address this issue. These specialized strains can contain 10-15% CBG by dry weight, compared to trace amounts in standard hemp varieties. The improved genetics have made CBG extraction more economically viable for mid-sized manufacturers.

Pricing reflects these production realities. CBG isolate currently sells for 2-3 times the price of CBD isolate in wholesale markets, according to hemp industry pricing indices. That premium flows through to consumer products, where CBG topicals often retail 30-50% higher than comparable CBD formulations.

What's Next

Industry observers expect continued growth in CBG product development, particularly in blended formulations that combine multiple cannabinoids. Several brands now market "full spectrum minus THC" topicals featuring CBG, CBD, and minor cannabinoids like CBC and CBN.

The regulatory environment remains uncertain. While hemp-derived cannabinoids under 0.3% THC are federally legal, the FDA hasn't established a clear framework for topical products. State regulations vary widely, with some requiring testing and labeling standards while others have minimal oversight.

Consumer education will likely determine CBG's long-term trajectory in the topicals market. The cannabinoid lacks CBD's name recognition, and many shoppers remain unfamiliar with how different cannabinoids function. Brands investing in educational content and transparent lab testing may gain advantage as the category matures.

---

This article is based on original reporting by hightimes.com.